Condition
Community Acquired Pneumonia (CAP) clinical trials and research
As of November 12, 2026, Find a Trial lists 9 Community Acquired Pneumonia (CAP) clinical trials that are recruiting, at sites in 31 countries (most in Canada (3), France (2), Italy (2)). 1 was first registered in the last 30 days. By phase: Phase 3 (2), Phase 4 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 9Clinical trials
- 1New in 30 days
- 31Countries
Newest Community Acquired Pneumonia (CAP) clinical trials
All recruiting trials (9)
-
Chest X-ray vs ultra-low-dose chest CT in adults with possible pneumonia in the ER
This study tests whether an ultra-low-dose chest CT can replace chest X-ray for adults in the emergency department when pneumonia is a possibility, to see if it changes how much staff time is spent on imaging.
-
Lefamulin Post-Market Surveillance in Community-Acquired Pneumonia
This study follows people with community-acquired pneumonia who are being treated with lefamulin to see how it works in real-world clinical use.
-
Shortening antibiotic courses for common throat and chest infections in primary care with doctor–pharmacist teamwork and viral‑circulation updates
This project will test whether giving primary care doctors and pharmacists extra information about circulating viruses plus a shared protocol helps shorten antibiotic courses for patients with common respiratory infections.
-
Improving treatment for children with community-acquired pneumonia in emergency rooms
This project tests a new care pathway to see if emergency departments can safely give fewer antibiotics to children aged 6 months–18 years with non-severe community-acquired pneumonia who are sent home.
-
Antibiotic strategies for young children with pneumonia in outpatient care
This trial will see if a 'watch-and-wait' Safety Net Antibiotic Prescribing (SNAP) approach can safely reduce antibiotic use compared with immediate antibiotics in children aged 12 months to under 6 years with mild community-acquired pneumonia.
-
Hydrocortisone vs prednisolone for severe community-acquired pneumonia
This trial tests whether hydrocortisone or prednisolone helps adults with severe community-acquired pneumonia live longer and have fewer side effects within 30 days.
-
ARGONAUT: Italian registry of pneumonia in people with weakened immune systems
This project will collect clinical and lab data to see how community-acquired pneumonia affects hospitalized adults with weakened immune systems.
-
Reducing artery inflammation after community-acquired pneumonia
This trial will test whether taking Vascepa twice daily for six months can reduce artery inflammation in adults hospitalized with community-acquired pneumonia.
-
Evaluating treatments for severe community-acquired pneumonia in ICU patients
This study tests different treatment options for ICU patients with severe pneumonia to see which ones work best, including special strategies for those with COVID-19.
Related topics
Quick answers
How many Community Acquired Pneumonia (CAP) clinical trials are recruiting right now?
9, as of November 12, 2026. 1 of them was first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 31 countries. The most sites are in Canada (3 trials), France (2 trials), Italy (2 trials), United States (2 trials), Denmark (2 trials). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 3: 2, Phase 4: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.